Error

According to the U.S. Food and Drug Administration (FDA), Duexis — a single-tablet combination product containing ibuprofen, a nonsteroidal anti‐inflammatory drug (NSAID), and famotidine, a histamine H2–receptor blocker — will no longer be manufactured. Read more...

Earlier this year, the American Geriatrics Society (AGS) published an update to the AGS Beers Criteria® for potentially inappropriate medication (PIM) use in older adults (65 years of age and older). Older adults are more likely to experience unwanted adverse effects and be more sensitive to certain medications. Read more...

On August 8, the Center for Medicare & Medicaid Services (CMS) released an updated Non-Group Health Plan (NGHP) User Guide, Version 7.2, which includes important updates. Read more...

FDA approves additional over-the-counter naloxone products Read more...

The 2Q 2023 Brand-Generic Pipeline update Read more...

Extended-release Brixadi has been approved by the FDA for subcutaneous injection in patients recovering from Opioid Use Disorder as part of their treatment plan. Read more...

On June 6, the Center for Medicare & Medicaid Services (CMS) released an updated Non-Group Health Plan (NGHP) User Guide, Version 7.2, which includes important changes. Read more...

In Episode #20,  the Policy Guys visit with Andrew Sabolic, former Deputy Director at Florida’s Division of Workers’ Compensation and current Executive Director at WCI for an in-depth discussion about the workers’ comp regulations – how they are formulated, refined and written into law, as well as useful tips on how best to work with state regulators. Read more...

The Centers for Medicare and Medicaid Services (CMS) released an updated Workers’ Compensation Medicare Set Aside (WCMSA) Reference Guide, version 3.9, dated 5/15/2023, which includes two significant changes. Read more...

On April 27, 2023, CMS released the NGHP Applicable Plan Appeals Reference Guide as a way to streamline the appeal process, which includes types of appeals and documentation needed to support appeals. Read more...